Risk factors of hepatotoxicity with ribociclib in hormone receptor–positive breast cancer

Wei-Chi Lin, Yu-Li Chang, Sheng-Fan Wang, Chia-Chen Hsu, Chian-Ying Chou, Ling-Ming Tseng, Ta-Chung Chao

Open source

DOI: 10.1097/jcma.0000000000001417
Published: 2026-08-24
Container: Journal of the Chinese Medical Association
Publisher: Ovid Technologies (Wolters Kluwer Health)
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1097/jcma.0000000000001417,
  title = {Risk factors of hepatotoxicity with ribociclib in hormone receptor–positive breast cancer},
  author = {Wei-Chi Lin and Yu-Li Chang and Sheng-Fan Wang and Chia-Chen Hsu and Chian-Ying Chou and Ling-Ming Tseng and Ta-Chung Chao},
  year = {2026},
  journal = {Journal of the Chinese Medical Association},
  doi = {10.1097/jcma.0000000000001417},
  url = {https://doi.org/10.1097/jcma.0000000000001417}
}

RIS

TY  - JOUR
TI  - Risk factors of hepatotoxicity with ribociclib in hormone receptor–positive breast cancer
AU  - Wei-Chi Lin
AU  - Yu-Li Chang
AU  - Sheng-Fan Wang
AU  - Chia-Chen Hsu
AU  - Chian-Ying Chou
AU  - Ling-Ming Tseng
AU  - Ta-Chung Chao
PY  - 2026
JO  - Journal of the Chinese Medical Association
DO  - 10.1097/jcma.0000000000001417
UR  - https://doi.org/10.1097/jcma.0000000000001417
ER  -

APA

Lin, W., Chang, Y., Wang, S., Hsu, C., Chou, C., Tseng, L., & Chao, T. (2026). Risk factors of hepatotoxicity with ribociclib in hormone receptor–positive breast cancer. Journal of the Chinese Medical Association. https://doi.org/10.1097/jcma.0000000000001417

Source records

crossref · retrieved 2026-09-27T16:02:31.856Z